A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

Author
Spapen, Herbert
Dugernier, Thierry
Laterre, Pierre-Francois
Depuydt, Pieter
Vincent, Jean-Louis
Bogar, Lajos
Szabo, Zsuzsanna
Volgyes, Barbara
Manez, Rafael
RAMAZANOĞLU, ATİLLA
TOPELİ İSKİT, ARZU
Mastruzzo, Maria A.
Jasovich, Abel
Remolif, Christian G.
del Carmen Soria, Liliana
Andresen Hernandez, Max A.
Ruiz Balart, Carolina
Kremer, Ildiko
Molnar, Zsolt
von Sonnenburg, Frank
Lyons, Arthur
Joannidis, Michael
Welte, Tobias
Klingler, Anton
Hochreiter, Romana
Westritschnig, Kerstin
Cakar, Nahit
Burgmann, Heinz
Rello, Jordi
Krenn, Claus-Georg
Locker, Gottfried
Pilger, Ernst
Madl, Christian
Balica, Laura
Metadata
Show full item record
Abstract
Background: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired infections. IC43 has proven immunogenicity and tolerability in healthy volunteers, patients with burns, and patients with chronic lung diseases. In order to assess the immunogenicity and safety of IC43 in patients who are most at risk of acquiring Pseudomonas infections, it was evaluated in mechanically ventilated ICU patients.
URI
http://hdl.handle.net/20.500.12627/110760
https://doi.org/10.1186/s13054-017-1601-9
Collections